Announced Date: 2025-10-08 (October 8, 2025)<\/p>\n\n\n\n
Asset Name: BTK inhibitor Orelabrutinib; Oral IL-17AA\/AF inhibitor; Oral TYK2 inhibitor.<\/p>\n\n\n\n
Licensor (Seller): InnoCare Pharma Limited (China)<\/p>\n\n\n\n
Licensee (Buyer): Zenas BioPharma, Inc. (US) <\/p>\n\n\n\n
.<\/p>\n\n\n\n
Leading Asset: Orelabrutinib <\/p>\n\n\n\n
<Orelabrutinib is approved for B cell malignancies in mainland China and Singapore><\/p>\n\n\n\n
Asset Modality: Small Molecule<\/p>\n\n\n\n
Asset Target: Bruton\u2019s Tyrosine Kinase (BTK) inhibitor<\/p>\n\n\n\n
Potential Indication: Multiple Sclerosis (MS) <\/p>\n\n\n\n
Current Stage: Phase III initiated<\/p>\n\n\n\n
.<\/p>\n\n\n\n
Asset 2: Oral IL-17AA\/AF inhibitor (ZB021)<\/p>\n\n\n\n
Asset Modality: Small Molecule<\/p>\n\n\n\n
Current Stage: IND enabling studies<\/p>\n\n\n\n
.<\/p>\n\n\n\n
Asset 3: Oral TYK2 inhibitor (ZB022)<\/p>\n\n\n\n
Asset Modality: Small Molecule<\/p>\n\n\n\n
Current Stage: IND enabling studies<\/p>\n\n\n\n
.<\/p>\n\n\n\n
Scope of Authority:<\/p>\n\n\n\n
InnoCare Pharma granting Zenas global development and commercialization rights to orelabrutinib for Multiple Sclerosis (MS) and across all therapeutic areas other than oncology. <\/p>\n\n\n\n
Zenas also secured rights to a novel, oral, IL-17AA\/AF inhibitor, and an oral, brain-penetrant, TYK2 inhibitor.<\/p>\n\n\n\n
Zenas will have the exclusive right to develop, manufacture and commercialize orelabrutinib in the field of MS globally, and non-oncology fields in all territories outside Greater China and Southeast Asia, while InnoCare retains full global rights in the field of oncology. <\/p>\n\n\n\n
Zenas will also have the exclusive right to develop, manufacture and commercialize the oral, IL-17AA\/AF inhibitor in all territories outside Greater China and Southeast Asia, and the oral, brain-penetrant, TYK2 inhibitor globally.<\/p>\n\n\n\n
.<\/p>\n\n\n\n
Payment Detail:<\/p>\n\n\n\n
Zenas will pay InnoCare upfront and near-term milestone payments of up to $100 million in cash, and up to 7,000,000 shares of Zenas common stock. <\/p>\n\n\n\n
The total of the upfront payment, near term milestone and potential development and regulatory milestone payments, along with potential commercial sales achievement milestone payments for all three programs, exceeds $2 billion.<\/p>\n\n\n\n
In addition, InnoCare is entitled to receive tiered royalties of up to high teens percentages on annual net sales of the licensed products.<\/p>\n\n\n\n
.<\/p>\n\n\n\n
Link:<\/p>\n\n\n\n
Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis | Wed, 10\/08\/2025 – 05:00<\/a><\/p>\n\n\n\n .<\/p>\n\n\n\n